Arjan Boltjes"These data identify developmental lineage as a key determinant of sensitivity to anti-GD2 based immunotherapies and credential #EZH2 inhibitors for clinical testing in combination with anti-GD2 antibody to enhance outcomes for children with #neuroblastoma".
An article that I had missed, by Mabe et al., linking #mesenchymal #tumour cell state, #GD2 expression, #ST8SIA1 expression, and #immunotherapy #TherapyResistance.
https://www.nature.com/articles/s43018-022-00405-x
Sadly, not open access.
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1 - Nature Cancer
Mabe et al. find that GD2 levels correlate with lineage plasticity in neuroblastoma and identify ST8SIA1 as the key enzyme in GD2 synthesis. EZH2 inhibition in mesenchymal neuroblastoma cells elevates ST8SIA1, synergizing with anti-GD2 antibodies.